Minnesota Adrenoleukodystrophy Registry Study (MARS) and Biobank

Related Clinical Trial
Study of Disease Progression in Adults With Inherited Forms of Spastic Paraplegia Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy Modeling Macrophages Activation Pattern in X-linked Adrenoleukodystrophy and Metachromatic Leukodystrophy SMART-ALD – A New Lifestyle Intervention to Improve Quality of Life in Women With X-linked Adrenoleukodystrophy (X-ALD) Quality of Life in Women With X-linked Adrenoleukodystrophy A Clinical Study in Male Pediatric Patients With Cerebral X-linked Adrenoleukodystrophy (Cald) to Assess the Effects of MIN-102 Treatment on Disease Progression Prior to Human Stem Cell Transplant (HSCT) Plasma Exchange With Albumin in AMN Patients Stem Cell Transplant for Inborn Errors of Metabolism Human Placental-Derived Stem Cell Transplantation Precision Exercise in Children With Malignant Hemopathies Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Adrenoleukodystrophy Effect of Pioglitazone Administered to Patients With Adrenomyeloneuropathy MD1003-AMN MD1003 in Adrenomyeloneuropathy A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients. Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD) A Clinical Trial for AMN: Validation of Biomarkers of Oxidative Stress, Efficacy and Safety of a Mixture of Antioxidants Autologous Hematopoietic Stem Cell Gene Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy Repetitive Transcranial Magnetic Stimulation as Therapy in Hereditary Spastic Paraplegia and Adrenomyeloneuropathy Clinical Study and Gene Mutation Analysis of Adrenoleukodystrophy in Taiwanese Children Early Diagnosis Of Childhood Cerebral ALD Randomized Study of Beta Interferon and Thalidomide in Patients With Adrenoleukodystrophy Multi-center Clinical Study on the Diagnosis and Treatment Management of Rare Neurological Disease in Children HSCT for High Risk Inherited Inborn Errors Longitudinal Natural History Study of Patients With Peroxisome Biogenesis Disorders (PBD) UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases The Effect of Bezafibrate on the Level of Very Long Chain Fatty Acids (VLCFA) in X-linked Adrenoleukodystrophy (X-ALD) A Phase III Trial of Lorenzo’s Oil in Adrenomyeloneuropathy Lentiviral Gene Therapy for X-ALD MT2014-14 IT-MSC for Advanced Cerebral Adrenoleukodystrophy (cALD) Safety and Pharmacodynamic Study of Sobetirome in X-Linked Adrenoleukodystrophy (X-ALD) Newborn Screening for Adrenoleukodystrophy A Study to Prospectively Assess Disease Progression in Male Children With X-ALD Long-term Follow-up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product Exercise Study of Function and Pathology for Women With X-linked Adrenoleukodystrophy Expanded Access for Lorenzo’s Oil (GTO/GTE) in Adrenoleukodystrophy Minnesota Adrenoleukodystrophy Registry Study (MARS) and Biobank A Pilot Study of Vitamin D in Boys With X-linked Adrenoleukodystrophy Effect of Glycerol Trierucate on Clinical Course of Adrenoleukodystrophy

Brief Title

Adrenoleukodystrophy National Registry Study

Official Title

Adrenoleukodystrophy National Registry Study

Brief Summary

      The aim of this registry to understand the natural history and disease progression in ALD and
      potentially develop bio-markers using the biospecimens collected using this registry.
    

Detailed Description

      This is a prospective, non-therapeutic protocol designed to create and maintain a registry of
      participants with Adrenoleukodystrophy (ALD) and known/presumed mutation for ALD. This study
      also involves maintaining a prospective biorepository to collect and store buccal swab,
      blood, stool and urine samples as well. In this protocol, pediatric (including infants),
      adolescents and adult patients with confirmed or presumed ALD (based on positive VLCFA
      testing and/or confirmed mutation) will be offered potential study participation.
      Additionally, presumed mutation for ALD (based on pedigree or confirmed mutation) will be
      offered potential study participation. After appropriate consent (online or in-person),
      subjects will be requested to provide a medical history (with authorization of release of
      medical records), longitudinal biospecimens, and permission to perform laboratory analyses on
      these samples. The overall goal is to understand the natural disease course in affected and
      unaffected patients (identified patients and relatives with a diagnosis of ALD), as well as
      women with ALD to assemble a resource of clinical, medical, and biological data from the
      participants. This study also aims to understand the outcomes of this disease, as well as
      possibly develop biomarkers to identify prognostic markers for disease progression, which may
      help develop effective interventions. The biospecimen bank and registry will provide access
      to samples and data for the ongoing studies as well as will provide an important resource for
      the future research.
    


Study Type

Observational [Patient Registry]


Primary Outcome

Collect Clinical and Epidemiological Data


Condition

ALD (Adrenoleukodystrophy)

Intervention

Medical Record Abstraction

Study Arms / Comparison Groups

 Adrenoleukodystrophy
Description:  All patients living in the United States diagnosed with adrenoleukodystrophy, either by newborn screen, based on family history or otherwise, are eligible to participate in this study.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Other

Estimated Enrollment

1000

Start Date

May 1, 2019

Completion Date

February 2030

Primary Completion Date

February 2030

Eligibility Criteria

        Inclusion Criteria

          -  Age 0 - 100

          -  ALD patients or family member meeting any of the following criteria:

               -  Any patient diagnosed with ALD (confirmed by positive VLCFA testing and/or
                  genetic mutation).

               -  Known or presumed mutation with ALD based on pedigree or confirmed mutation in
                  ABCD1 gene

          -  Participants living in the United States and territories

        Exclusion Criteria

          -  Patients diagnosed with ALD who lack the capacity to consent/assent AND do not have a
             designated legally authorized representative or guardian.

          -  Patients who have undergone BMT or other cellular therapy .

          -  Patients not fluent in English who are unable to consent in-person at the BMT Journey
             Clinic.

          -  Patients who are illiterate

          -  Patient determined by the PI or designee to be unlikely to complete required study
             components (due to language barriers, compliance issues, etc.)
      

Gender

All

Ages

N/A - N/A

Accepts Healthy Volunteers

No

Contacts

, 612-626-2961, [email protected]

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT03789721

Organization ID

2019NTLS027

Secondary IDs

MT2019-01

Responsible Party

Sponsor

Study Sponsor

Masonic Cancer Center, University of Minnesota


Study Sponsor

, , 


Verification Date

April 2021